[go: up one dir, main page]

DE69528888D1 - Regulierung von nf-kappa-b aktivität durch proteasome - Google Patents

Regulierung von nf-kappa-b aktivität durch proteasome

Info

Publication number
DE69528888D1
DE69528888D1 DE69528888T DE69528888T DE69528888D1 DE 69528888 D1 DE69528888 D1 DE 69528888D1 DE 69528888 T DE69528888 T DE 69528888T DE 69528888 T DE69528888 T DE 69528888T DE 69528888 D1 DE69528888 D1 DE 69528888D1
Authority
DE
Germany
Prior art keywords
activity
proteasome
kappa
regulation
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69528888T
Other languages
English (en)
Other versions
DE69528888T2 (de
DE69528888T3 (de
Inventor
Vito J Palombella
Alfred L Golberg
Thomas P Maniatis
Oliver Rando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22782682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69528888(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Harvard University filed Critical Harvard University
Publication of DE69528888D1 publication Critical patent/DE69528888D1/de
Publication of DE69528888T2 publication Critical patent/DE69528888T2/de
Application granted granted Critical
Publication of DE69528888T3 publication Critical patent/DE69528888T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Detergent Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Distillation Of Fermentation Liquor, Processing Of Alcohols, Vinegar And Beer (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69528888T 1994-03-18 1995-03-17 Regulation der NF-KB Aktivität durch Proteasomen Expired - Lifetime DE69528888T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US210381 1994-03-18
US08/210,381 US6660268B1 (en) 1994-03-18 1994-03-18 Proteasome regulation of NF-KB activity
PCT/US1995/003315 WO1995025533A1 (en) 1994-03-18 1995-03-17 PROTEASOME REGULATION OF NF-λB ACTIVITY

Publications (3)

Publication Number Publication Date
DE69528888D1 true DE69528888D1 (de) 2003-01-02
DE69528888T2 DE69528888T2 (de) 2003-10-23
DE69528888T3 DE69528888T3 (de) 2006-10-05

Family

ID=22782682

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69528888T Expired - Lifetime DE69528888T3 (de) 1994-03-18 1995-03-17 Regulation der NF-KB Aktivität durch Proteasomen

Country Status (11)

Country Link
US (2) US6660268B1 (de)
EP (1) EP0750507B2 (de)
JP (1) JPH09510710A (de)
AT (1) ATE228002T1 (de)
CA (1) CA2184727C (de)
DE (1) DE69528888T3 (de)
DK (1) DK0750507T4 (de)
ES (1) ES2182897T5 (de)
PT (1) PT750507E (de)
SI (1) SI0750507T2 (de)
WO (1) WO1995025533A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6838477B2 (en) * 1995-04-12 2005-01-04 President And Fellows Of Harvard College Lactacystin analogs
US5834487A (en) * 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones
AU741802B2 (en) 1997-02-15 2001-12-13 Millennium Pharmaceuticals, Inc. Treatment of infarcts through inhibition of NF-kappaB
US6831057B2 (en) 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
US6207412B1 (en) * 1997-11-13 2001-03-27 The Regents Of The University Of California Identification of a G protein-coupled receptor transcriptionally regulated by protein tyrosine kinase signaling in hematopoietic cells
US6075150A (en) * 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
EP0982317A1 (de) * 1998-08-26 2000-03-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalente Proteasome Inhibitore
EP0995757A3 (de) * 1998-08-26 2002-05-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalente Proteasom Inhibitore
WO2000023614A1 (en) 1998-10-20 2000-04-27 Millennium Pharmaceuticals, Inc. Method for monitoring proteasome inhibitor drug action
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US20030165492A1 (en) * 2000-06-08 2003-09-04 Alberto Panerai Method of treatment of alzheimer's disease with a protein extractable from mammalian organs
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
WO2004043374A2 (en) 2002-11-06 2004-05-27 Dana-Farber Cancer Institute, Inc. Methods and compositions for treating cancer using proteasome inhibitors
JP5717937B2 (ja) 2002-12-06 2015-05-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害療法を用いた患者の同定、判定および治療方法
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
WO2005077389A1 (en) * 2004-02-06 2005-08-25 The University Of Chicago An anti-inflammatory, cytoprotective factor derivable from a probiotic organism
WO2006062732A2 (en) * 2004-11-19 2006-06-15 Synta Pharmaceuticals Corp. Compounds acting at the centrosome
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
DE102005009784B4 (de) 2005-03-03 2009-06-18 Technische Universität Darmstadt Peptid-Mimetika, Verfahren zur deren Herstellung, diese enthaltende pharmazeutische Zusammensetzung und deren Verwendung als Inhibitoren von Proteasomen und zur Induktion von Apoptose
KR101274417B1 (ko) 2005-11-09 2013-06-17 프로테올릭스, 인코퍼레이티드 효소 저해를 위한 화합물
BRPI0713309A2 (pt) 2006-06-19 2012-04-17 Proteolix Inc compostos para inibição de enzimas
KR20150131405A (ko) 2007-10-04 2015-11-24 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
US9181296B2 (en) * 2008-03-26 2015-11-10 Novozymes A/S Stabilized liquid enzyme compositions
AU2009308516B2 (en) 2008-10-21 2016-08-25 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
EP2516449A1 (de) 2009-12-22 2012-10-31 Cephalon, Inc. Proteasehemmer und verfahren zu ihrer herstellung, reinigung und verwendung
PH12012501719A1 (en) 2010-03-01 2012-11-12 Onyx Therapeutics Inc Compounds for immunoproteasome inhibition
AU2011245630B2 (en) 2010-04-07 2014-07-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
WO2013071163A2 (en) 2011-11-11 2013-05-16 Millennium Pharamaceuticals, Inc. Biomarkers of response to proteasome inhibitors
JP5540340B2 (ja) * 2012-02-29 2014-07-02 独立行政法人理化学研究所 炎症性疾患の判定方法
JP2015524394A (ja) 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
ES2885423T3 (es) 2013-02-07 2021-12-13 Massachusetts Gen Hospital Procedimientos para la expansión o el empobrecimiento de células T reguladoras
US12174188B2 (en) 2013-10-17 2024-12-24 The General Hospital Corporation Methods of identifying subjects responsive to treatment for type 1 diabetes and compositions for treating the same
WO2016187068A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
WO2017059132A1 (en) 2015-09-29 2017-04-06 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for bcg therapy
CN116715767A (zh) 2016-05-13 2023-09-08 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
CA3199881A1 (en) * 2020-11-24 2022-06-02 Pierre Cau Compounds for treating segmental progeroid syndromes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510130A (en) 1983-05-20 1985-04-09 Genetic Diagnostics Corporation Promoting animal and plant growth with leupeptin
US6150090A (en) 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
SE8702550D0 (sv) 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
WO1989008147A1 (en) 1988-03-01 1989-09-08 Whitehead Institute For Biomedical Research ACTIVITION OF NF-kB PRECURSOR
ZA897515B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
JP2701932B2 (ja) 1989-04-10 1998-01-21 サントリー株式会社 タンパク質分解酵素阻害剤
IL97428A0 (en) 1990-03-05 1992-06-21 Cephalon Inc Chymotrypsin-like proteases and their inhibitors
EP0564561A4 (en) 1990-12-28 1994-08-10 Georgia Tech Res Inst Peptides ketoamides, ketoacids, and ketoesters
CA2098609A1 (en) 1990-12-28 1992-06-29 Raymond T. Bartus Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
WO1992013549A1 (en) * 1991-02-07 1992-08-20 Research Corporation Technologies, Inc. Inhibition of cell proliferation by hydrophobic peptides
EP0504938A3 (en) * 1991-03-22 1993-04-14 Suntory Limited Prophylactic and therapeutic agent for bone diseases comprising di- or tripeptide derivative as active ingredient
AU2140592A (en) 1991-05-17 1992-12-30 Chiron Corporation Inhibitor of nf-kappa b transcriptional activator and uses thereof
EP0650368A1 (de) * 1992-06-24 1995-05-03 Cortex Pharmaceuticals, Inc. Verwendung von calpain inhibitoren in der inhibition und behandlung von medizinischen zuständen die mit einer erhöhten calpainaktivität assoziiert sind
DE4311835A1 (de) 1993-04-07 1994-10-13 Boehringer Ingelheim Int Verfahren zur Inhibierung der Transkription von Genen
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
KR970060809A (ko) * 1996-01-19 1997-08-12 김광호 자동응답전화기에서 예약 시각에 등록 음성메세지 전송 방법

Also Published As

Publication number Publication date
DE69528888T2 (de) 2003-10-23
SI0750507T1 (en) 2003-04-30
WO1995025533A1 (en) 1995-09-28
AU2121595A (en) 1995-10-09
EP0750507A4 (de) 1999-03-31
US20040097420A1 (en) 2004-05-20
CA2184727C (en) 2007-08-28
PT750507E (pt) 2003-04-30
DK0750507T4 (da) 2006-07-03
AU682264B2 (en) 1997-09-25
EP0750507B1 (de) 2002-11-20
EP0750507A1 (de) 1997-01-02
US6660268B1 (en) 2003-12-09
DK0750507T3 (da) 2003-02-17
ES2182897T5 (es) 2006-10-16
DE69528888T3 (de) 2006-10-05
CA2184727A1 (en) 1995-09-28
EP0750507B2 (de) 2006-03-01
ATE228002T1 (de) 2002-12-15
ES2182897T3 (es) 2003-03-16
SI0750507T2 (sl) 2006-08-31
JPH09510710A (ja) 1997-10-28

Similar Documents

Publication Publication Date Title
DE69528888D1 (de) Regulierung von nf-kappa-b aktivität durch proteasome
NO963814L (no) Inhibitor av det 26S proteolytiske kompleks og 20S proteasomet inneholdt deri
DE69734766D1 (de) Hemmstoff und stimulator der proliferation haematopoietischer stammzellen und deren anwendungen
DE69736669D1 (de) Zelladhäsionsinhibitoren
ATE216215T1 (de) Verminderung des haarwuchses
ATE305031T1 (de) Alkalische amylase aus bacellus
ATE173392T1 (de) Hemmung des haarwuchses
DE69310677D1 (de) Behandlung von Brennstoffgasen, insbesondere für Brennstoffzellen und Vorrichtung dafür
DK0772396T3 (da) Fremgangsmåde til regulering af immunfunktion
DE69818445D1 (de) Verwendung von verbindungen die an ein zytoplasmatischen dipeptidase binden zur potenzierung des immunantworts
ATE275932T1 (de) Verwendung bestimmter polyalkoxy compolymere für die behandlung von schuppen
ATE207964T1 (de) Produktion von ammonium-acrylat
ATE234637T1 (de) Verbesserungen von oder in bezug auf endometrialfunktion
PT784677E (pt) Inibidor da proliferacaode celulas estaminais e suas utilizacoes
DE69927831D1 (de) Modulierung von gedächtnis-effector t-zellen unter verwendung eines cd2-bindungsagentes
AU5243493A (en) Regulation of immunoglobin production by interleukin-4 and interleukin-9
MY112975A (en) Mild refining of triglyceride oil
DK0629242T3 (da) Fremgangsmåde til forøgelse af en plantes tidlige modning og/eller til reduktion af det oplagrede nitratindhold i en plante
ATE230955T1 (de) Gewebeablationssystem
ES2124670B1 (es) Aparato y metodo para mantener la carga de una bateria.
ATE548033T1 (de) Therapeutisches verfahren zur hemmung von nf- kappa b
ATE294189T1 (de) Kristallisation von proteinen
DE69938827D1 (de) Verwendung von inhibitoren von asparaginyl-endopeptidase aus säugetieren zur modulierung des immunsystemen
NO985929L (no) Nye former av organiske salter av N'N-diacetylcystin
SU1264575A1 (ru) Способ иммобилизации клеток

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8328 Change in the person/name/address of the agent

Representative=s name: KUDLEK & GRUNERT PATENTANWAELTE PARTNERSCHAFT, 803